ArticlemedRxiv : the preprint server for health sciences2025
A highly divergent cryptic SARS-CoV-2 lineage exhibits strong receptor binding and immune evasion.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
SARS-CoV-2 genomic surveillance in wastewater enables the identification of cryptic lineages, often with numerous mutations not observed in circulating variants. Here, we discovered a unique cryptic SARS-CoV-2 lineage (designated NJ) from New Jersey wastewater that carries many rare mutations and exhibits the highest binding affinity to the hACE2 receptor among all tested SARS-CoV-2 variant RBDs, including the latest Omicron lineages. Moreover, NJ shows extensive evasion against all five major classes of neutralizing antibodies to SARS-CoV-2. Deep mutational scanning further demonstrates the involvement of epistasis in the evolution of the NJ-RBD. Crystal structures of NJ-RBD in complex with hACE2 and with a broadly neutralizing antibody CC25.4 reveal key amino acid substitutions that affect receptor binding, antibody evasion, and explain its unique molecular characteristics. Overall, these findings not only elucidate the structural and functional features of a cryptic SARS-CoV-2 lineage, but also provide insights into potential future evolution of SARS-CoV-2.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.